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1. Introduction 
As it was reported by Chow (2002), the notion that food could serve as medicine was first 
conceived thousands of years ago by the Greek philosopher and father of medicine, 
Hippocrates, who once wrote: 'Let food be thy medicine, and let medicine be thy food'. 
However, during recent times, the concept of food having medicinal value has been reborn 
as 'functional foods'. The list of health benefits accredited to functional food continues to 
increase, and the gut is an obvious target for the development of  functional foods, because 
it acts as an interface between  the diet and all other body functions. One of the most  
promising areas for the development of functional food  components lies in the use of 
probiotics and prebiotics which scientific researches have demonstrated therapeutic 
evidence. Nowadays, consumers are aware of the link among lifestyle, diet and good health, 
which explains the emerging demand for products that are able to enhance health beyond 
providing basic nutrition. Besides the nutritional valaes, ingestion of lactic acid bacteria 
(LAB) and their fermented foods has been suggested to confer a range of health benefits 
including immune system modulation, increased resistance to malignancy, and infectious 
illness (Soccol, et al., 2010). LAB were first isolated from milk. They can be found in 
fermented products as meat, milk products, vegetables, beverages and bakery products. 
LAB occur naturally in soil, water, manure, sewage, silage and plants. They are part of the 
microbiota on mucous membranes, such as the intestines, mouth, skin, urinary and genital 
organs of both humans and animals, and may have a beneficial influence on these 
ecosystems. LAB that grow as the adventitious microflora of foods or that are added to 
foods as cultures are generally considered to be harmless or even an advantage for human 
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health. Since their discovery, LAB has been gained mush interest in various applications, as 
starter cultures in food and feed fermentations, pharmaceuticals, probiotics and as biological 
control agents. In food industry, LAB are widely used as starters to achieve favorable 
changes in texture, aroma, flavor and acidity (Leory and De Vuyst, 2004). However, there 
has been an important interest in using bacteriocin and/or other inhibitory substance 
producing LAB for non-fermentative biopreservation applications. Du to their antimicrobial 
and antioxidant activities some LAB strains are used in food biopreservation. However, 
LAB are generally regarded as safe (GRAS) to the consumer and during storage, they 
naturally dominate the microflora of many foods (Osmanağaoğlu and Beyatli, 1999; Parada 
et al., 2007). Many of the indications for probiotic activity have been obtained from effects 
observed in various clinical situations. Even, there are few strains that have officially gained 
the status of pharmaceutical preparation; each of these effects is gradually being supported 
by a number of clinical studies or human intervention trials, performed in a way that 
resembles the traditional pharmacological approach (placebo-controlled, double blind, 
randomized trials) and the strains used in these studies belong to different microbial 
species, but are mostly lactic acid bacteria (Mercenier et al, 2003). 
2. LAB as probiotic agents 
2.1. Overview of probiotics 
The most tried and tested manner in which the gut microbiota composition may be 
influenced is through the use of  live microbial dietary additions, as probiotics. In fact, the 
concept dates back as far as prebiblical ages. The first records of ingestion of live bacteria by 
humans are over 2,000 years old. However, at the beginning of this century probiotics were 
first put onto a scientific basis by the work of Metchnikoff (1908). He hypothesised that the 
normal gut microflora could exert adverse effects on the host and that consumption of 
‘soured milks’ reversed this effect. The word ‘‘probiotics’’ was initially used as an anonym 
of the word ‘‘antibiotic’’. It is derived from Greek words pro and biotos and translated as 
‘‘for life’’. The origin of the first use can be traced back to Kollath (1953), who used it to 
describe the restoration of the health of malnourished patients by different organic and 
inorganic supplements. Later, Vergin (1954) proposed that the microbial imbalance in the 
body caused by antibiotic treatment could have been restored by a probiotic rich diet; a 
suggestion cited by many as the first reference to probiotics as they are defined nowadays. 
Similarly, Kolb recognized detrimental effects of antibiotic therapy and proposed the 
prevention by probiotics (Vasiljevic and Shah, 2008) Later on, Lilly and Stillwell (1965)  
defined probiotics as “…microorganisms promoting the growth of other microorganisms”. 
Following recommendations of a FAO/WHO (2002) working group on the evaluation of 
probiotics in food, probiotics, are live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host (Sanders, 2008; Schrezenmeir and De Vrese, 
2001). The idea of health-promoting effects of LAB is by no means new, as Metchnikoff 
proposed that lactobacilli may fight against intestinal putrefaction and contribute to long 
life. Such microorganisms may not necessarily be constant inhabitants of the gut, but they 
should have a “…beneficial effect on the general and health status of man and animal”  
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Probiotic Human disease in 
which benefit is 
shown 
Animal model in which 
benefit is shown 
Yeast 
Saccharomyces boulardii Clostridium difficile 
infection 
Citrobacter rodentium-induced 
colitis 
Gram-negative bacteria 
Escherichia coli Nissle 1917 NA DSS-induced colitis 
Gram-positive bacteria 
Bifidobacteria bifidum NA Rat model of necrotizing 
enterocolitis 
Bifidobacteria infantis IBS29 NA 
Lactobacillus rhamnosus GG  
(used with lactoferrin) 
Sepsis in very low 
birth weight infants
NA 
Lactococcus lactis (engineered to  
produce IL-10 or trefoil factors) 
Crohn's disease DSS-induced colitis and IL-
10−/− mice (spontaneous IBD)  
Lactobacillus plantarum 299v Antibiotic-
associated diarrhea 
IL-10−/− mice (spontaneous 
IBD) 
Lactobacillus acidophilus NA Visceral hyperalgesia 40 and 
C. rodentium-induced colitis 
Lactobacillus rhamnosus Pediatric antibiotic-
associated diarrhea 
– 
Lactobacillus casei NA DNBS-induced colitis 
Bacillus polyfermenticus NA DSS-induced colitis and 
TNBS-induced colitis 
Combination regimens 
Lactobacillus rhamnosus GG combined 
with Bifidobacterium lactis 
Bacterial infections NA 
Lactobacillus rhamnosus combined with 
Lactobacillus helveticus 
NA C. rodentium-induced colitis,  
chronic stress, and early life 
stress 
VSL#3 (Lactobacillus casei, Lactobacillus 
plantarum, Lactobacillus acidophilus, 
Lactobacillus bulgaricus, Bifidobacterium 
longum, Bifidobacterium breve, 
Bifidocacterium infantis and Streptococcus 
thermophilus) 
Pouchitis and 
pediatric ulcerative 
colitis 
DSS-induced colitis, IL-10−/− 
mice (spontaneous IBD; DNA 
only), and SAMP mouse 
model of spontaneous IBD 
Abbreviations: DNBS, dinitrobenzene sulfonic acid; DSS, dextran sodium sulfate; IL-10, interleukin 10; NA, not 
available; TNBS, trinitrobenzene sulfonic acid. 
Table 1. Selected organisms that are used as probiotic agents (Gareau et al., 2010). 
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(Holzapfel et al., 2001; Belhadj et al., 2010). Other definitions advanced through the years 
have been restrictive by specification of mechanisms, site of action, delivery format, method, 
or host. Probiotics have been shown to exert a wide range of effects. The mechanism of 
action of probiotics (e.g, having an impact on the intestinal microbiota or enhancing immune 
function) was dropped from the definition to encompass health effects due to novel 
mechanisms and to allow application of the term before the mechanism is confirmed. 
Physiologic benefits have been attributed to dead microorganisms. Furthermore, certain 
mechanisms of action (such as delivery of certain enzymes to the intestine) may not require 
live cells. However, regardless of functionality, dead microbes are not probiotics (Sanders, 
2008). In relation to food, probiotics are considered as “viable preparations in foods or 
dietary supplements to improve the health of humans and animals”. According to these 
definitions, an impressive number of microbial species are considered as probiotics. 
(Holzapfel et al., 2001). For gastrointestinal ecosysteme, however, the most important 
microbial species that are used as probiotics are lactic acid bacteria (LAB) (Table 1). 
2.2. Selection of probiotics 
Many in vitro tests are performed when screening for potential probiotic strains. The first 
step in the selection of a probiotic LAB strain is the determination of its taxonomic 
classification, which may give an indication of the origin, habitat and physiology of the 
strain. All these characteristics have important consequences on the selection of the novel 
strains (Morelli, 2007). An FAO/WHO (2002) expert panel suggested that the specificity of 
probiotic action is more important than the source of microorganism. This conclusion was 
brought forward due to uncertainty of the origin of the human intestinal microflora since 
the infants are borne with virtually sterile intestine. However, the panel also underlined a 
need for improvement of in vitro tests to predict the performance of probiotics in humans. 
While many probiotics meet criteria such as acid and bile resistance and survival during 
gastrointestinal transit, an ideal probiotic strain remains to be identified for any given 
indication. Furthermore, it seems unlikely that a single probiotic will be equally suited to all 
indications; selection of strains for disease-specific indications will be required (Shanahan, 
2003).  
The initial screening and selection of probiotics includes testing of the following important 
criteria: phenotype and genotype stability, including plasmid stability; carbohydrate and 
protein utilization patterns; acid and bile tolerance and survival and growth; intestinal 
epithelial adhesion properties; production of antimicrobial substances; antibiotic resistance 
patterns; ability to inhibit known pathogens, spoilage organisms, or both; and 
immunogenicity. The ability to adhere to the intestinal mucosa is one of the more important 
selection criteria for probiotics because adhesion to the intestinal mucosa is considered to be 
a prerequisite for colonization (Tuomola et al., 2001). The table below (Table 2) indicates key 
creteria for sellecting probiotic candidat for commercial application, and figure 1 presents 
major and cardinal steps for sellecting probiotic candidats. 
It is of high importance that the probiotic strain can survive the location where it is presumed 
to be active. For a longer and perhaps higher activity, it is necessary that the strain can 
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proliferate and colonise at this specific location. Probably only host-specific microbial strains 
are able to compete with the indigenous microflora and to colonise the niches. Besides, the 
probiotic strain must be tolerated by the immune system and not provoke the formation of 
antibodies against the probiotic strain. So, the host must be immuno-tolerant to the probiotic. 
On the other hand, the probiotic strain can act as an adjuvant and stimulate the immune 
system against pathogenic microorganisms. It goes without saying that a probiotic has to be 
harmless to the host: there must be no local or general pathogenic, allergic or 
mutagenic/carcinogenic reactions provoked by the microorganism itself, its fermentation 
products or its cell components after decrease of the bacteria (Desai, 2008). 
General  Property
Safety criteria Origin
Pathogenicity and infectivity 
Virulence factors—toxicity, metabolic activity and 
intrinsic properties, i.e., antibiotic resistance 
Technological criteria  Genetically stable strains
Desired viability during processing and storage 
Good sensory properties 
Phage resistance 
Large-scale production
Functional criteria Tolerance to gastric acid and juices
Bile tolerance 
Adhesion to mucosal surface 
Validated and documented health effects 
Desirable physiological 
criteria 
 
 
Immunomodulation
Antagonistic activity towards gastrointestinal 
pathogens, i.e., Helicobacter pylori, Candida albicans 
Cholesterol metabolism 
Lactose metabolism 
Antimutagenic and anticarcinogenic properties 
Table 2. Key and desirable criteria for the selection of probiotics in commercial applications (Vasiljevic 
and Shah, 2008). 
When probiotic strains are selected, attributes important for efficacy and technological 
function must be assessed and a list of characteristics required for all probiotic functions is 
required. Basic initial characterization of strain identity and taxonomy should be conducted, 
followed by evaluation with validated assays both in studies of animal models and in 
controlled studies in the target host. In vitro assays are frequently conducted that have not 
been proved to be predictive of in vivo function. Technological robustness must also be 
determined, such as the strain’s ability to be grown to high numbers, concentrated, 
stabilized, and incorporated into a final product with good sensory properties, if applicable, 
and to be stable, both physiologically and genetically, through the end of the shelf life of the 
product and at the active site in the host. Assessment of stability can also be a challenge, 
since factors such as chain length and injury may challenge the typical assessment of colony-
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forming units, as well as in vivo function (Sanders, 2008). Dose levels of probiotics should be 
based on levels found to be efficacious in human studies. One dose level cannot be assumed 
to be effective for all strains. Furthermore, the impact of product format on  
 
Figure 1. Scheme of the Guidelines for the Evaluation of Probiotics for Food Use. (Adapted from, 
Collado et al., 2009). 
probiotic function has yet to be explored in depth. The common quality-control parameter of 
colony-forming units per gram may not be the only parameter indicative of the efficacy of 
the final product. Other factors, such as probiotic growth during product manufacture, 
coating, preservation technology, metabolic state of the probiotic, and the presence of other 
functional ingredients in the final product, may play a role in the effectiveness of a product. 
More research is needed to understand how much influence such factors have on in vivo 
efficacy (Sanders, 2008). 
2.3. Potential mechanisms of action of probiotics 
A wide variety of potential beneficial health effects have been attributed to probiotics (Table 
3). Claimed effects range from the alleviation of constipation to the prevention of major life-
threatening diseases such as inflammatory bowel disease, cancer, and cardiovascular 
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incidents. Some of these claims, such as the effects of probiotics on the shortening of 
intestinal transit time or the relief from lactose maldigestion, are considered well-
established, while others, such as cancer prevention or the effect on blood cholesterol levels, 
need further scientific backup (Leroy et al., 2008). The mechanisms of action may vary from 
one probiotic strain to another and are, in most cases, probably a combination of activities, 
thus making the investigation of the responsible mechanisms a very difficult and complex 
task. In general, three levels of action can be distinguished: probiotics can influence human  
 
Probiotic organisms can provide a beneficial effect on intestinal epithelial cells in numerous ways. a: Some strains can 
block pathogen entry into the epithelial cell by providing a physical barrier, referred to as colonization resistance or b: 
create a mucus barrier by causing the release of mucus from goblet cells. c: Other probiotics maintain intestinal 
permeability by increasing the intercellular integrity of apical tight junctions, for example, by upregulating the 
expression of zona-occludens 1 (a tight junction protein), or by preventing tight junction protein redistribution thereby 
stopping the passage of molecules into the lamina propria. d: Some probiotic strains have been shown to produce 
antimicrobial factors. e: Still other strains stimulate the innate immune system by signaling dendritic cells, which then 
travel to mesenteric lymph nodes and lead to the induction of TREG cells and the production of anti-inflammatory 
cytokines, including IL-10 and TGF-β. f: Some probiotics (or their products) may also prevent (left-hand side) or 
trigger (right-hand side) an innate immune response by initiating TNF production by epithelial cells and inhibiting (or 
activitating) NFκB in Mφ and dampening (or priming) the host immune response by influencing the production of IL-
8 and subsequent recruitment of Nφ to sites of intestinal injury. Abbreviations: Mφ, macrophage; Nφ, neutrophil; 
TREG cell, regulatory T cell. Reproduced from, Gareau M. G., P. M. Sherman & W. A. Walker (2010) Nature Reviews 
Gastroenterology and Hepatology 7, 503-514. 
Figure 2. Potential mechanisms of action of probiotics. 
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Health benefit  Proposed mechanism(s) 
Cancer prevention Inhibition of the transformation of pro-carcinogens 
into active carcinogens, binding/inactivation of 
mutagenic compounds, production of anti-mutagenic 
compounds, suppression of growth of pro-
carcinogenic bacteria, reduction of the absorption of 
carcinogens, enhancment of immune function, 
influence on bile salt concentrations 
Control of irritable bowel 
syndrome 
Modulation of gut microbiota, reduction of intestinal 
gas production 
 
Management and prevention of 
atopic diseases 
 
Modulation of immune response 
Management of inflammatory 
bowel diseases (Crohn’s disease, 
ulcerative colitis, pouchitis) 
 
Modulation of immune response, modulation of gut 
 microbiota 
Prevention of heart 
diseases/influence on blood 
cholesterol levels 
Assimilation of cholesterol by bacterial cells, 
deconjugation of bile acids by bacterial acid 
hydrolases, 
cholesterol-binding to bacterial cell walls, reduction 
of hepatic cholesterol synthesis and/or redistribution 
of cholesterol from plasma to liver through influence 
of the bacterial production of short-chain fatty acids 
 
Prevention of urogenital tract 
disorders 
Production of antimicrobial substances, competition 
for adhesion sites, competitive exclusion of pathogens 
 
Prevention/alleviation of 
diarrhoea 
caused by bacteria/viruses 
Modulation of gut microbiota, production of 
antimicrobial  substances, competition for adhesion 
sites, stimulation of mucus secretion, modulation of 
immune response 
 
Prevention/treatment of 
Helicobacter pylori infections 
Production of antimicrobial substances, stimulation of 
the mucus secretion, competition for adhesion sites, 
stimulation of specific and non-specific immune 
responses 
Relief of lactose indigestion Action of bacterial β-galactosidase(s) on lactose 
Shortening of colonic transit 
time 
Influence on peristalsis through bacterial metabolite 
production 
Table 3. Potential and established health benefits associated with the usage of probiotics  (Leroy et al., 
2008).  
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health by interacting with other microorganisms present on the site of action, by 
strengthening mucosal barriers, and by affecting the immune system of the host (Leroy et 
al., 2008), and the figure 2 shows the most important mechanisms by whiche probiotics 
exerce their action inside the gut. 
3. Probiotics and gut health  
3.1. Gut microbiota 
The human gastrointestinal tract is inhabited by a complex and dynamic population of 
around 500-1000 of different microbial species which remain in a complex equilibrium. It 
has been estimated  that bacteria account for 35–50% of the volume content of the human 
colon. These include Bacteroides, Lactobacillus, Clostridium,  Fusobacterium,  Bifidobacterium,  
Eubacterium,  Peptococcus,  Peptostreptococcus,  Escherichia and  Veillonella. The bacterial  strains 
with identified beneficial properties include mainly Bifidobacterium and Lactobacillus species. 
The dominant microbial composition of the intestine have been shown to be stable over time 
during adulthood, and the microbial patterns are unique for each individual. However, 
there are numerous external factors that have potential to influence the microbial 
composition in the gut as host genetics, birth delivery  mode, diet, age, antibiotic treatments 
and also, other microorganisms as probiotics. (Collado et al., 2009). The intestine is one of 
the main surfaces of contact with exogenous agents (viruses, bacteria, allergens) in the 
human body. It has a primary role in the host defense against external aggressions by means 
of the intestinal mucosa, the local immune system, and the interactions with the intestinal 
microbiota (resident and in transitbacteria). Gut microbiota influences human health 
through an impact on the gut defense barrier, immune function, nutrient utilization and 
potentially by direct signaling with the gastrointestinal epithelium (Collado et al., 2009). 
Only a limited fraction of bacterial phyla compose the major intestinal microbiota. In 
healthy adults, 80% of phylotypes belong to four major phylogenetic groups, which are the 
Clostiridium leptum, Clostridium coccoides, Bacteroides and Bifidobacteria groups. However, a 
large fraction of dominant phylotypes is subject specific. Also, studies have found that 
mucosal microbiota is stable along the distal gastrointestinal tract from ileum to rectum, but 
mucosa-associated microbiota is different from fecal microbiota. The difference has been 
estimated to be between 50–90%.  
The intestinal microbiota is not homogeneous. The number of bacterial cells present in the 
mammalian gut shows a continuum that goes from 101 to 103 bacteria per gram of contents 
in the stomach and duodenum, progressing to 104 to 107 bacteria per gram in the jejunum 
and ileum and culminating in 1011 to 1012 cells per gram in the colon (Figure 3a). 
Additionally, the microbial composition varies between these sites. In addition to the 
longitudinal heterogeneity displayed by the intestinal microbiota, there is also a great deal 
of latitudinal variation in the microbiota composition (Figure 3b). The intestinal epithelium 
is separated from the lumen by a thick and physicochemically complex mucus layer. The 
microbiota present in the intestinal lumen differs significantly from the microbiota attached 
and embedded in this mucus layer as well as the microbiota present in the immediate  
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a: variations in microbial numbers and composition across the length of the gastrointestinal tract. b: longitudinal 
variations in microbial composition in the intestine. c: temporal aspects of microbiota establishment and maintenance 
and factors influencing microbial composition. (Sekirov et al., 2010). 
Figure 3. Spatial and temporal aspects of intestinal microbiota composition. 
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proximity of the epithelium. For instance, Bacteroides, Bifidobacterium, Streptococcus, members 
of Enterobacteriacea, Enterococcus, Clostridium, Lactobacillus, and Ruminococcus were all found 
in feces, whereas only Clostridium, Lactobacillus, and Enterococcus were detected in the mucus 
layer and epithelial crypts of the small intestine (Sekirov et al., 2010). Colonization of the 
human gut with microbes begins immediately at birth (Figure 3c). Upon passage through 
the birth canal, infants are exposed to a complex microbial population. After the initial 
establishment of the intestinal microbiota and during the first year of life, the microbial 
composition of the mammalian intestine is relatively simple and varies widely between 
different individuals and also with time. However, after one year of age, the intestinal 
microbiota of children starts to resemble that of a young adult and stabilizes (Figure 3c) 
(Sekirov et al., 2010). 
3.2. Survival and antagonism effects of probiotics in the gut 
The intestinal epithelium is the largest mucosal surface in the human body, provides an 
interface between the external environment and the host. The gut epithelium is constantly 
exposed to foreign microbes and antigens derived from digested foods. Thus, the gut 
epithelium acts as a physical barrier against microbial invaders and is equipped with 
various elements of the innate defense system. In the gut, two key elements govern the 
interplay between environmental triggers and the host: intestinal permeability and intestinal 
mucosal defense. Resident bacteria can interact with pathogenic microorganisms and 
external antigens to protect the gut using various strategies. 
According to the generally accepted definition of a probiotic, the probiotic microorganism 
should be viable at the time of ingestion to confer a health benefit. Although not explicitly 
stated, this definition implies that a probiotic should survive GI tract passage and, colonize 
the host epithelium. A variety of traits are believed to be relevant for surviving GI tract 
passage, the most important of which is tolerance both to the highly acidic conditions 
present in the stomach and to concentrations of bile salts found in the small intestine. These 
properties have consequently become important selection criteria for new probiotic 
functionality. In addition to tolerating the harsh physical-chemical environment of the GI 
tract, adherence to intestinal mucosal cells would be necessary for colonization and any 
direct interactions between the probiotic and host cells leading to the competitive exclusion 
of pathogens and/or modulation of host cell responses. Moreover, As enteropathogenic 
Escherichia coli are known to bind to epithelial cells via mannose receptors, probiotic strains 
with similar adherence capabilities could inhibit pathogen attachment and colonization at 
these binding sites and thereby protect the host against infection (Marco et al., 2006). 
Probiotic bacteria can antagonize pathogenic bacteria by reducing luminal pH, inhibiting 
bacterial adherence and translocation, or producing antibacterial substances and defensins. 
One of the mechanisms by which the gut flora resists colonization by pathogenic bacteria is 
by the production of a physiologically restrictive environment, with respect to pH, redox 
potential, and hydrogen sulfide production. Probiotic bacteria decrease the luminal pH, as 
has been demonstrated in patients with ulcerative colitis (UC) following ingestion of the 
 
Lactic Acid Bacteria – R & D for Food, Health and Livestock Purposes 208 
probiotic preparation VSL#3. In a fatal mouse Shiga toxin-producing E. coli O157:H7 
infection model, the probiotic Befidobacterium breve produced a high concentration of 
acetic acid, consequently lowering the luminal pH. This pH reduction was associated with 
increased animal survival (Ng et al., 2009). 
Production of antimicrobial compounds, termed bacteriocins, by probiotic bacteria is also 
likely to contribute to their beneficial activity. Several bacteriocins produced by different 
species from the genus Lactobacillus have been described. The inhibitory activity of these 
bacteriocins varies; some inhibit taxonomically related Gram-positive bacteria, and some are 
active against a much wider range of Gram-positive and Gram-negative bacteria as well as 
yeasts and molds. For example, the probiotic L. salivarius subsp. salivarius UCC118 produces 
a peptide that inhibits a broad range of pathogens such as Bacillus, Staphylococcus, 
Enterococcus, Listeria, and Salmonella species. Lacticin 3147, a broad-spectrum bacteriocin 
produced by Lactococcus lactis, inhibits a range of genetically distinct Clostridium difficile 
isolates from healthy subjects and patients with IBD. A further example is the antimicrobial 
effect of Lactobacillus species on Helicobacter pylori infection of gastric mucosa, achieved by 
the release of bacteriocins and the ability to decrease adherence of this pathogen to epithelial 
cells (Gotteland et al., 2006). Probiotics can reduce the epithelial injury that follows exposure 
to E. coli O157:H7 and E. coli O127:H6. The pretreatment of intestinal (T84) cells with lactic 
acid-producing bacteria reduced the ability of pathogenic E. coli to inject virulence factors 
into the cells or to breach the intracellular tight junctions. Adhesion and invasion of an 
intestinal epithelial cell line (Intestine 407) by adherent invasive E. coli isolated from patients 
with Crohn’s disease (CD) was substantially diminished by co- or preincubation with the 
probiotic strain E. coli Nissle 1917 (Wehkamp et al., 2004 ; Schlee et al., 2007). These findings 
demonstrate that probiotics prevent epithelial injury induced by attaching-effacing bacteria 
and contributes to an improved mucosal barrier and provide a means of limiting access of 
enteric pathogens (Sherman et al., 2005). 
4. Probiotics and the mucous layer 
Most mucosal surfaces are covered by a hydrated gel formed by mucins. Mucins are 
secreted by specialized epithelial cells, such as gastric foveolar mucous cells and intestinal  
goblet cells, Goblet cells are found along the entire length of the intestinal tract, as well as 
other mucosal surfaces. Mucins, are abundantly core glycosylated (up to 80% wt/wt) and 
either localized to the cell membrane or secreted into the lumen to form the mucous layer 
(Turner, 2009). Of the 18 mucin-type glycoproteins expressed by humans, MUC2 is the 
predominant glycoprotein found in the small and large bowel mucus. The NH2- and 
COOH-termini are not glycosylated to the same extent, but are rich in cysteine residues that 
form intra- and inter-molecular disulfide bonds. These glycan groups confer proteolytic 
resistance and hydrophilicity to the mucins, whereas the disulfide linkages form a matrix of 
glycoproteins that is the backbone of the mucous layer (Ohland and MacNaughton, 2010). 
Although small molecules pass through the heavily glycosylated mucus layer with relative 
ease, bulk fluid  flow is limited and thereby contributes to the development of an unstirred 
layer of fluid at the epithelial cell surface. As the unstirred layer is protected from 
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convective mixing forces, the diffusion of ions and small solutes is slowed (Turner, 2009). 
This gel layer provides protection by shielding the epithelium from potentially harmful 
antigens and molecules including bacteria from directly contacting the epithelial cell layer, 
while acting as a lubricant for intestinal motility. Mucins can also bind the epithelial cell 
surface carbohydrates and form the bottom layer, which is firmly attached to the mucosa, 
whereas the upper layer is loosely adherent. The mucus is the first barrier that intestinal 
bacteria meet, and pathogens must penetrate it to reach the epithelial cells during infection 
(Ohland and MacNaughton, 2010). 
Probiotics may promote mucus secretion as one mechanism to improve barrier function and 
exclusion of pathogens. In support of this concept, probiotics have been shown to increase 
mucin expression in vitro, contributing to barrier function and exclusion of pathogens. 
Several studies showed that increased mucin expression in the human intestinal cell lines 
Caco-2 (MUC2) and HT29 (MUC2 and 3), thus blocking pathogenic E. coli invasion and 
adherence. However, this protective effect was dependent on probiotic adhesion to the cell 
monolayers, which likely does not occur in vivo (Mack et al., 2003; Mattar et al., 2002). 
Conversely, another study showed that L. acidophilus A4 cell extract was sufficient to 
increase MUC2 expression in HT29 cells, independent of attachment (Kim et al., 2008). 
Additionally, intestinal trefoil factor 3 (TFF3) is coexpressed with MUC2 by colonic goblet 
cells and is suggested to promote wound repair (Gaudier et al., 2005 ; Kalabis et al., 2006). 
However, healthy rats did not display increased colonic TFF3 expression after stimulation 
by VSL#3 probiotics (Caballero-Franco et al., 2007). Furthermore, mice treated with 1% 
dextran sodium sulfate (DSS) to induce chronic colitis did not exhibit increased TFF3 
expression or wound healing when subsequently treated with VSL#3. This observation 
indicates that probiotics do not enhance barrier function by up-regulation of TFF3, nor are 
they effective at healing established inflammation. Therefore, use of current probiotics is 
likely to be effective only in preventing inflammation as shown by studies in animal models 
(Ohland and MacNaughton, 2010). 
5. Interaction of probiotic bacteria with gut epithelium 
The composition of the commensal gut microbiota is probably influenced by the 
combination of food practices and other factors like the geographical localization, various 
levels of hygiene or various climates. The host-microbe interaction is of primary importance 
during neonatal period. The establishment of a normal microbiota provides the most 
substantial antigenic challenge to the immune system, thus helping the gut associated 
lymphoid tissus (GALT) maturation. The intestinal microbiota contributes to the anti-
inflammatory character of the intestinal immune system. Several immunoregulatory 
mechanisms, including regulatory cells, cytokines, apoptosis among others, participate in 
the control of immune responses by preventing the pathological processes associated with 
excessive reactivity. An interesting premise for probiotic physiological action is their 
capacity to modulate the immune system. Consequently, many studies have focused on the 
effects of probiotics on diverse aspects of the immune response. Following consumption of 
probiotic products, the interaction of these bacteria with intestinal enterocytes initiates a 
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host response, since intestinal cells produce various immunomodulatory molecules when 
stimulated by bacteria (Delcenseri et al., 2009). Furthermore, the indigenous microbiota is a 
natural resistance factor against potential pathogenic microorganisms and provides 
colonization resistance, also known as gut barrier, by controlling the growth of 
opportunistic microorganisms. It has been suggested that commensal bacteria protect their 
host against microbial pathogens by interfering with their adhesion and toxic effects 
(Myllyluoma, 2007). 
 
A fraction of ingested probiotics are able to interact with intestinal epithelial cells (IECs) and dendritic cells (DCs), 
depending on the presence of a dynamic mucus layer. Probiotics can occasionally encounter DCs through two routes: 
DCs residing in the lamina propria sample luminal bacterial antigens by passing their dendrites between IECs into the 
gut lumen, and DCs can also interact directly with bacteria that have gained access to the dome region of the gut-
associated lymphoid tissue (GALT) through specialized epithelial cells, termed microfold or M cells. The interaction of 
the host cells with microorganism-associated molecular patterns (MAMPs) that are present on the surface 
macromolecules of probiotic bacteria will induce a certain molecular response. The host pattern recognition receptors 
(PRRs) that can perceive probiotic signals include Toll-like receptors (TLRs) and the C type lectin DC-specific 
intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN). Some molecular responses of IECs depend on the 
subtype of cell, for example, Paneth cells produce defensins and goblet cells produce mucus. Important responses of 
DCs against probiotics include the production of cytokines, major histocompatibility complex molecules for antigen 
presentation, and co-stimulatory molecules that polarize T cells into T helper or CD4+CD25+ regulatory T cells in the 
mesenteric lymph nodes (MLNs) or subepithelial dome of the GALT. IFNγ, interferon-γ; IL, interleukin; TGFb; 
transforming growth factor-β. Reproduced from: S. Lebeer, J. Vanderleyden & S. C. J. De Keersmaecker (2010). Host 
interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nature Reviews Microbiology 8, 
171-184.  
Figure 4. Interaction of probiotic bacteria with IECs and DCs from the GALT. 
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The tight epithelial cell barrier forms the another line of defence between the gut luminal 
contents and the host. Epithelial cells lining the gastrointestinal tract are able to respond to 
infection by initiating either nonspecific or specific host-defence response (Kagnoff and 
Eckmann 1997, Strober 1998). Bacterial adhesion to the host cell or recognition by the host 
cell is often an essential first stage in the disease process. A wide range of gastrointestinal 
cell surface constituents, such as several glygoconjucates, can serve as receptors for bacterial 
adherence (Servin and Coconnier 2003, Pretzer et al., 2005). Furthermore, epithelial cells 
express constitutively host pattern recognition receptors (PRRS), such as Toll-like receptors 
(TLR). These are a family of transmembrane receptors that recognize repetitive patterns, i.e. 
the pathogen-associated molecular patterns present in diverse microbes, including gram-
positive and gram-negative bacteria (Bäckhed and Hornef 2003, Takeda et al., 2003). TLRs 
are also found on innate immune cells, such as dendritic cells and macrophages (Vinderola 
et al., 2005). TLR4 recognizes lipopolysaccharide and gram-negative bacteria, while TLR2 
recognizes a variety of microbial components, such as peptidoglycan and lipoteichoic acids, 
from gram-positive bacteria (Abreu 2003, Matsuguchi et al., 2003, Takeda et al., 2003). Also, 
several other TLRs with specific actions are known, such as TLR5, which responds to the 
bacterial flagella (Rhee et al., 2005), and TLR9, which is activated by bacterially derived 
short DNA fragments containing CpG sequences (Pedersen et al.,  2005). Other known 
recognition receptors are nucleotide-binding oligomerization domain proteins, which 
recognize both gram-positive and gram-negative bacteria. They are located in cell cytoplasm 
and are implicated in the induction of defensins. Increased epithelial barrier permeability is 
frequently associated with gastrointestinal disorders contributing to both disease onset and 
persistence (Lu and Walker 2001, Berkes 2003). The gatekeeper of the paracellular pathway 
is the tight junction, which is an apically located cell-cell junction between epithelial cells. 
The tight junction permits the passage of small molecules, such as ions, while restricting the 
movement of large molecules, such as antigens and microorganisms, which can cause 
inflammation. The integral membrane protein family, which are mainly claudins, occluding 
and zonula occludens 1, are implicated in the formation of the paracellular channels (Berkes 
et al., 2003). 
6. Origine and safety of probiotics  
An old dogma of probiotic selection has been that the probiotic strains should be of “human 
origin”. One may argue that from evolutionary point of view, describing bacteria to be of 
human origin does not make much sense at all. The requirement for probiotics to be of 
human origin relates actually to the isolation of the strain rather than the “origin” itself. 
Usually, the strains claimed to be “of human origin” have been isolated from faecal samples 
of healthy human subjects, and have therefore been considered to be “part of normal 
healthy human gut microbiota”. In reality the recovery of a strain from a faecal sample does 
not necessarily mean that this strain is part of the normal microbiota of this individual, since 
microbes passing the GI tract transiently can also be recovered from the faecal samples 
(Forssten et al., 2011). In practice it is impossible to know the actual origin of the probiotic 
strains, regardless of whether they have been isolated from faecal samples, fermented dairy 
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products or any other source for that matter. Isolation of a strain from faeces of a healthy 
individual is also not a guarantee of the safety of the  strain—such a sample will also always 
contain commensal microbes which can act  as opportunistic pathogens, or even low levels 
of true pathogens, which are present in the individual at sub-clinical levels. Therefore, it has 
been recommend that instead of concentrating on the first point of isolation, the selection 
processes for new potential probiotic strains should mainly focus on the functional 
properties of the probiotic strains rather than the “origin” (Forssten et al., 2011; Ouwehand 
and Lahtinen 2008). 
As viable, probiotic bacteria have to be consumed in large quantities, over an extended 
period of time, to exert beneficial effects; the issue of the safety of these microorganisms is of 
primary concern (Leroy et al., 2008). Until now, reports of a harmful effect of these microbes 
to the host are rare. However, many species of the genera Lactobacillus, Leuconostoc, 
Pediococcus, Enterococcus, and Bifidobacterium were isolated frequently from various 
types of infective lesions. According to Gasser (1994), L. rhamnosus, L. acidophilus, L. 
plantarum, L. casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus lactis, 
and Leuconostoc mesenteroides are some examples of probiotic bacteria isolated from 
bacterial endocarditis; L. rhamnosus, L. plantarum, Leuconostoc. mesenteroides, 
Pediococcus acidilactici, Bifidobacterium eriksonii, and Bifidobacterium adolescentis have 
been isolated from bloodstream infections and many have been isolated from local 
infections. Although minor side effects of the use of probiotics have been reported, 
infections with probiotic bacteria occur and invariably only in immunocompromised 
patients or those with intestinal bleeding (Leroy et al., 2008).  
An issue of concern regarding the use of probiotics is the presence of chromosomal, 
transposon, or plasmid-located antibiotic resistance genes amongst the probiotic 
microorganisms. At this moment, insufficient information is available on situations in 
which these genetic elements could be mobilised, and it is not known if situations could 
arise where this would become a clinical problem (Leroy et al., 2008). When dealing with 
the selection of probiotic strains, the FAO/WHO Consultancy recommends that probiotic 
microorganisms should not harbor transmissible drug resistance genes encoding 
resistance to clinically used drugs (FAO/WHO, 2002). For the assessment of the safety of 
probiotic microorganisms and products, FAO/WHO has formulated guidelines, 
recommending that probiotic strains should be evaluated for a number of parameters, 
including antibiotic susceptibility patterns, toxin production, metabolic and haemolytic 
activities, and infectivity in immunocompromised animals (FAO/WHO, 2002). In vitro 
safety screenings of probiotics may include, among others, antibiotic resistance assays, 
screenings for virulence factors, resistance to host defence mechanisms and induction of 
haemolysis. Several different animal models have been utilized in the safety assessment of 
probiotics. These include models of immunodeficiency, endocarditis, colitis and liver 
injury. In some cases even acute toxicity of probiotics has been assessed. Last but not 
least, also clinical intervention trials have yielded evidence on the safety of probiotics for 
human consumption (Forssten et al., 2011). 
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7. Conclusion 
The individual diversity of the intestinal microflora underscores the difficulty of identifying 
the entire human microbiota and poses barriers to this field of research. In addition, it is 
apparent that the actions of probiotics are species and strain specific. It is also apparent that 
even a single strain of probiotic may exert its actions via multiple, concomitant pathways. 
Probiotics have long been used as an alternative to traditional medicine with the goal of 
maintaining enteric homeostasis and preventing disease. However, the actual efficacy of this 
treatment in still debated. Clinical trials have shown that probiotic treatment can reduce the 
risk of some diseases, especially antibiotic-associated diarrhea, but conclusive evidence is 
impeded owing to the wide range of doses and strains of bacteria used. The mechanism of 
action is also an area of interest (Ohland and MacNaughton, 2010). Many studies, as 
discussed above, have shown that probiotics increase barrier function in terms of increased 
mucus, antimicrobial peptides, and sIgA production, competitive adherence for pathogens, 
and increased TJ integrity of epithelial cells. Current investigation into the mechanism of 
action of specific probiotics has focused on probiotic-induced changes in the innate immune 
functions involving TLRs and its downstream systems Like NF-κB, and other pathways 
(Yoon and Sun, 2011). Although the immunomodulatory effects of probiotics have been 
demonstrated in experimental animal models of allergy, autoimmunity, and IBD, 
information from clinical trials in humans is scarce. Furthermore, some studies suggest that 
probiotics could induce detrimental effects. Therefore, more research, especially in the form 
of well-designed clinical trials, is needed to evaluate the efficacy and safety of probiotics 
(Ezendam and Van Loveren, 2008). With evolving knowledge, efective probiotic therapy 
will be possible in the future. 
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